Trans-arterial Embolization for Facet Joint Arthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new treatment for lower back pain caused by facet joint arthritis, a type of osteoarthritis affecting the spine. The study tests whether trans-arterial embolization, a procedure that blocks blood flow to certain areas using tiny particles, is safe and effective for pain relief. Suitable candidates have experienced persistent lower back pain for at least six months, unrelieved by other treatments like injections or nerve procedures, and have pain at no more than two levels of the lower back. As an unphased trial, this study allows patients to contribute to innovative research that could lead to new treatment options for lower back pain.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that trans-arterial embolization is safe for treating facet joint arthritis?
Research has shown that trans-arterial embolization (TAE) is generally safe for patients. In studies treating facet joint pain with TAE, patients experienced good safety outcomes. Most side effects were mild, such as temporary pain at the treatment site. The research available has not directly linked any serious problems to this procedure. This treatment uses Embozene microparticles, which have been safely used in other medical procedures. While individual experiences may vary, current data suggests that TAE is a safe option for managing facet joint arthritis pain.12345
Why are researchers excited about this trial?
Trans-arterial Embolization is unique because it offers a new way to treat facet joint arthritis by directly targeting the blood vessels that supply the painful area. Unlike traditional treatments like physical therapy, pain medications, or steroid injections, this method uses Embozene microspheres to reduce blood flow to the facet joints, potentially reducing pain and inflammation. Researchers are excited about this approach because it may provide longer-lasting relief and reduce the need for more invasive procedures like surgery.
What evidence suggests that trans-arterial embolization is effective for facet joint arthritis?
Research has shown that trans-arterial embolization (TAE) can reduce pain from arthritis in the spine's facet joints. TAE blocks blood flow to specific areas using tiny particles, helping manage pain unresponsive to other treatments. Studies have found success with TAE in treating various muscle and joint pain, suggesting its potential for back pain from facet joint arthritis. This trial will specifically assess the safety and efficacy of TAE using Embozene microspheres for treating facetogenic low back pain. This noninvasive method offers an alternative for those seeking relief from chronic pain.12346
Are You a Good Fit for This Trial?
This trial is for individuals experiencing pain from facet arthropathy, which includes osteoarthritis or injury-related joint issues in the spine. Participants should have chronic lower back pain attributed to their facet joints and must have tried standard treatments without success.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo trans-arterial embolization using Embozene microparticles for the treatment of facetogenic pain
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Trans-arterial Embolization
Find a Clinic Near You
Who Is Running the Clinical Trial?
Northwell Health
Lead Sponsor